Publication details
Edoxaban
| Authors | |
|---|---|
| Year of publication | 2018 |
| Type | Article in Periodical |
| Magazine / Source | Interní medicína pro praxi |
| MU Faculty or unit | |
| Citation | |
| Keywords | anticoagulation;atrial fibrillation;cardioversion;trombembolic disease;edoxaban |
| Description | Blocade of factor Xa becomes a routine part of clinical praxis instead of cou-marine blockade with warfarin, providing a more benfitial and safer effect. The main indiactions are nonvalvular atrial fibrillation, deep venous trombosis, lung embolism and in recent time also electric cardioversion. Edoxaban appe-ars as the fourth drug which has also evidence based data from clinical trials. Its advantage is also a once daily dosage |